Allogene Therapeutics To Review Interim Futility Analysis For Phase 2 Trial Of Large B-Cell Lymphoma Treatment On April 13

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.

ALLO

0.00

Allogene Therapeutics To Review Interim Futility Analysis For Phase 2 Trial Of Large B-Cell Lymphoma Treatment On April 13